PROGRESSIVE'S EVENING STROLL DATE: 18 November, 2026

Market Snapshot:

The Index failed to sustain its brief recovery and turned lower. Losses extended through the session, with the Index settling at 25,227.95, down 159.45 points. PSU Banks led sectoral performance, while Pharma also closed higher. Metal and Capital Markets were the weakest sectors. Broader markets were mixed: Midcaps fell more than 1%, underperforming Nifty50, while Smallcaps declined 0.35% and outperformed.

HOW THE DAY TRENDED



INDICES

Index	Close	Points	%Chg.
Sensex	82031.81	(500.38)	**(0.61)**
Nifty50	25227.95	(159.45)	**(0.63)**
Nifty Midcap 100	60979.35	(750.65)	**(1.22)**
Nifty Small Cap 100	19331.60	(67.10)	**(0.35)**

SECTORAL GAINERS / LOSERS

Sectors	Close	Points	%Chg.
NIFTY PSU BANK	9542.80	56.20	**0.59**
NIFTY PHARMA	28200.50	43.40	**0.15**
NIFTY CAPITAL MKT	5783.00	(115.65)	**(1.96)**
NIFTY METAL	12222.30	(308.00)	**(2.46)**

NIFTY TOP GAINERS / LOSERS

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
SBIN	1135.00	**2.38**	TITAN	4648.10	**(5.30)**
CIPLA	1417.00	**2.09**	HDFC LIFE	575.50	**(3.29)**
TATA CONSUMER	1130.90	**1.66**	HINDALCO	900.00	**(2.99)**
APOLLO HOSPITAL	8821.00	**1.25**	BSE	3755.70	**(2.83)**

INDICES LEVELS FOR November 19, 2026

Nifty (future)	
Resistance	25540
Support	25050

Bank Nifty (future)	
Resistance	62400
Support	61250



PROGRESSIVE'S EVENING STROLL DATE: 18 November, 2026

KEY TAKEAWAYS OF THE DAY

- **Ashoka Buildcon becomes lowest bidder for Rs1,465cr NHAI Project in Gujarat:**

Ashoka Buildcon has emerged as the L-1 for a NHAI project involving the construction of an eight-lane, access-controlled expressway from Km 154.6 to Km 190 of the Vadodara-Mumbai Expressway (Jujuwa–Gandeva section) in Gujarat, on an engineering, procurement and construction (EPC) basis. The project has an EPC value of Rs1,465cr.

- **Ichnos Glenmark files USFDA application for solid tumour drug ISB 2301:**

Ichnos Glenmark Innovation (IGI), the biotechnology JV between Glenmark Pharmaceuticals and Ichnos Sciences, has submitted an investigational new drug (IND) application to the USFDA for its experimental cancer drug candidate ISB 2301, designed to target solid tumours. The company plans to initiate a Phase I clinical trial of the drug in patients with solid tumours in 2027, subject to regulatory clearance.

- **NDR Auto Components signs JV with South Korea's DYA for passenger car seats:**

NDR Auto Components is taking a majority stake in a new joint venture with South Korea's DYA to supply passenger car seats to major automakers like Kia and Hyundai in India. Under the proposed arrangement, NDR Auto Components will hold a 51% stake in the joint venture company, while DYA will own the remaining 49%. The initial equity investment in the proposed joint venture company will be Rs10cr.

- **Cipla's InvaGen New York facility gets USFDA's No Action Indicated classification:**

The company said the USFDA has classified the inspection of its wholly owned subsidiary InvaGen Pharmaceuticals Inc.'s manufacturing facility in Hauppauge, Long Island, New York, as No Action Indicated (NAI). The USFDA communicated the classification on November 17, 2026, following an inspection conducted at the facility from October 19 to October 22, 2026.

- **RITES signs MoU with National Mission for Clean Ganga to collaborate on project development:**

The company has signed MoU with the National Mission for Clean Ganga (NMCG) to strengthen collaboration in the development and execution of projects related to the mission. Under the agreement, RITES and NMCG will collaborate on the preparation of Detailed Project Reports (DPRs), tender documents and the provision of project engineering services.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai—400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500.

Grievance Officer:
Email: grievancecell@progressiveshares.com

